Add to a list

Inactive Instrument

Dechra Pharmaceuticals PLC Stock OTC Markets

DCHPF

GB0009633180

on all subscriptions*

Last days

Enjoy this offer

* See conditions under "Our services"

Valuation: Dechra Pharmaceuticals PLC

Market Cap	4.4B 5.92B 5.1B 4.69B 8.27B 559B 8.35B 55.49B 21.68B 274B 22.21B 21.74B 948B	P/E Ratio 2022	64.8x	P/E Ratio 2023	-150x
Enterprise Value	4.83B 6.5B 5.6B 5.15B 9.08B 614B 9.17B 60.91B 23.79B 301B 24.38B 23.86B 1,040B	EV / Sales 2022	5.8x	EV / Sales 2023	6.08x
Free-Float	-	Yield 2022	1.3%	Yield 2023	0.34%

* Estimated data More valuation ratios

Latest news : Dechra Pharmaceuticals PLC

05-19	Dechra Veterinary Products LLC Announces FDA Approval Of Cosacthen Cosyntropin Injection For Canine Patients	CI
03-30	Dechra Pharmaceuticals Limited Announces Termination of Jonathan David Lang as Director, Effective March 31, 2026	CI
03-11	Dechra Announces Consolidation Of Its Existing U.S. Office Footprint In Kansas City, Kan. And Portland, Maine	CI
03-11	Dechra Announces Plans to Relocate Its Global Headquarters from Northwich, England, to Boston, Massachusetts	CI
25-10-13	Intervacc Extends Equine Strangles Vaccine Distribution Deal with Dechra Pharmaceuticals	MT
25-10-13	Intervacc and Dechra Extend Distribution Agreement for Intervacc's Equine Strangle Vaccine Strangvac by Two Years	CI
25-09-02	Dechra Pharmaceuticals Limited completed the acquisition of Invetx, Inc. from a group of shareholders for approximately $530 million	CI
25-08-18	Dechra Pharmaceuticals PLC Launches Strangvac in Spain, Portugal and Slovenia	CI
25-06-16	Vaxxinova GmbH acquired Poultry Vaccines Business of Dechra Pharmaceuticals Limited.	CI
25-05-05	Dechra Pharmaceuticals to Launch Intervacc's Horse Vaccine in Finland	MT
25-05-05	Dechra Pharmaceuticals plc Launches Strangvac in Finland	CI
24-07-17	Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.	CI
24-06-09	Dechra Pharmaceuticals Limited Appoints Jonathan David Lang as Director	CI

More news

Analysts' recommendations: Dechra Pharmaceuticals PLC

23-06-27	Stifel Downgrades Dechra Pharmaceuticals to Hold from Buy, Lowers PT	MT
23-06-27	Analyst recommendations: Alphabet, Amgen, GSK, Moderna, Smiths Group...
23-06-27	UBS cuts BT'; HSBC starts Smiths with 'hold'	AN
23-03-07	Davy ups Purplebricks; JPMorgan cuts Clarkson	AN
23-01-12	UBS cuts Beazley; Berenberg likes Rio and BHP	AN

More recommendations

Press Releases: Dechra Pharmaceuticals PLC

23-12-27	Form 8.5 (EPT/RI) - Dechra Pharmaceuticals plc	AQ
23-10-30	Dechra Pharmaceuticals : 30 October 2023 Annual Report 2023 (Online)	PU
23-10-17	Dechra Pharmaceuticals : 17 October 2023 Annual Report 2023 ESEF XHTML	PU
23-10-17	Dechra Pharmaceuticals : 17 October 2023 Annual Report 2023	PU
23-09-06	Form 8.3 - Dechra Pharmaceuticals plc	AQ

More press releases

News in other languages: Dechra Pharmaceuticals PLC

24-01-12	BOLETÍN MATINAL : 12 de enero de 2024
23-12-13	Pharma und Gesundheit: weitere Konsolidierung
23-12-12	Farma en gezondheid: consolidatie gaat door
23-12-11	Farmaceutica e salute: continua il consolidamento
23-12-11	Farmacia y salud: La consolidación continúa

More news

Managers and Directors: Dechra Pharmaceuticals PLC

Manager	Title	Age	Since
Jesper Nordengaard CEO	Chief Executive Officer	-	2024-06-09
Paul Sandland DFI	Director of Finance/CFO	46	2019-04-02
Jamie Adams CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Paul Sandland BRD	Director/Board Member	46	2019-10-29
Lawson Macartney BRD	Director/Board Member	68	2016-11-30
Lisa Bright BRD	Director/Board Member	59	2019-01-31

More insiders

Dechra Pharmaceuticals PLC specializes in the manufacturing and marketing of veterinary pharmaceutical products. Net sales break down by family of products as follows: - companion animal products (74.6%); - food producing animal products (11.5%); - equine health products (7.3%); - animal feeds (5.1%); - other (1.5%): products manufactured by third parties. Net sales are distributed geographically as follows: the United Kingdom (8.5%), Germany (9.2%), Europe (31.2%), the United States (37.9%) and other (13.2%).

Employees

Sector

More about the company

	2022	2023
Net sales	682M 916M 790M 727M 1.28B 86.59B 1.29B 8.59B 3.36B 42.4B 3.44B 3.37B 147B	762M 1.02B 882M 812M 1.43B 96.71B 1.44B 9.6B 3.75B 47.36B 3.84B 3.76B 164B
Net income	58.2M 78.21M 67.41M 62.04M 109M 7.39B 110M 733M 286M 3.62B 293M 287M 12.53B	-27.9M -37.49M -32.31M -29.74M -52.41M -3.54B -52.93M -352M -137M -1.74B -141M -138M -6B
Net Debt	208M 280M 241M 222M 391M 26.44B 395M 2.62B 1.02B 12.95B 1.05B 1.03B 44.81B	430M 578M 498M 458M 808M 54.62B 816M 5.42B 2.12B 26.75B 2.17B 2.12B 92.56B

Dechra Pharmaceuticals PLC Stock OTC Markets

Stocks